PXD056098 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Expedited SARS-CoV-2 MPro inhibitor discovery through a modular, 'direct-to-biology' approach |
Description | Reactive fragment (RF) screening has emerged as an efficient method for ligand discovery across the proteome, irrespective of a target’s perceived tractability. To date, however, the efficiency of subsequent optimisation campaigns has largely been low-throughput, constrained by the need for synthesis and purification of target compounds. We report a high-throughput platform for ‘direct-to-biology’ (D2B) screening of cysteine-targeting chloroacetamide RFs, wherein synthesis is performed in 384-well plates allowing direct assessment in downstream biological assays without purification. Here, the developed platform was used to optimise inhibitors of SARS-CoV-2 main protease (MPro), an established drug target for the treatment of COVID-19. An initial RF hit was developed into a series of potent inhibitors, and further exploration using D2B screening enabled a ‘switch’ to a reversible inhibitor series. This example of ligand discovery for MPro illustrates the acceleration that D2B chemistry can offer for optimising RFs towards covalent inhibitor candidates, as well as providing future impetus to explore the evolution of RFs into non-covalent ligands. |
HostingRepository | PRIDE |
AnnounceDate | 2024-12-20 |
AnnouncementXML | Submission_2024-12-20_06:52:42.569.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Harry Wilders |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | biotinylated residue; iodoacetamide derivatized residue |
Instrument | timsTOF Pro 2 |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2024-09-23 08:40:08 | ID requested | |
⏵ 1 | 2024-12-20 06:52:42 | announced | |
Publication List
Keyword List
submitter keyword: Covalent Drug Discovery, Chemoproteomics,SARS-CoV-2 MPro |
Contact List
Jacob Theodore Bush |
contact affiliation | Chemical Biology, GSK, UK |
contact email | jacob.x.bush@gsk.com |
lab head | |
Harry Wilders |
contact affiliation | GSK The Francis Crick Institute |
contact email | harry.x.wilders@gsk.com |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/12/PXD056098 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD056098
- Label: PRIDE project
- Name: Expedited SARS-CoV-2 MPro inhibitor discovery through a modular, 'direct-to-biology' approach